Group 1 - BD has appointed Bilal Muhsin as executive vice president and president of the future Connected Care segment, effective July 2, 2025, as part of its New BD strategy [1][2] - Under Muhsin's leadership, BD Connected Care will focus on leveraging advanced analytics and AI solutions to enhance patient care efficiency and effectiveness, while exploring growth opportunities in areas like connected medication management and smart monitoring solutions [2][3] - Muhsin brings 25 years of experience from Masimo, where he held various leadership roles, including chief operating officer, and has a strong background in medical engineering and software development, holding over 50 patents [3][4] Group 2 - BD is recognized as one of the largest global medical technology companies, dedicated to improving medical discovery, diagnostics, and care delivery through innovative technology and solutions [5] - The company employs over 70,000 individuals and collaborates with global organizations to tackle significant health challenges, aiming to enhance outcomes, reduce costs, and improve healthcare access [5]

Core Viewpoint - Becton Dickinson and Company (BDX) is currently in the 17th phase of the 18-phase Adhishthana Cycle, indicating continued underperformance and consolidation until early June 2027 [1] Group 1: Adhishthana Cycle Analysis - BDX started its Adhishthana Cycle positively but experienced a critical shift entering Phase 8, where the expected bullish Cakra formation broke down [2][4] - The breakdown of the Cakra in Phase 8 led to over 1,400 days of sideways consolidation, confirming the structural weakness [6] - The Guna Triads, which assess the potential for reaching the highest price point in Phase 18, showed BDX's triads to be among the weakest compared to peers, lacking the necessary bullish momentum [9][10] Group 2: Monthly Chart and Future Outlook - On the monthly chart, BDX is in the Sankhya Period of Phase 2, characterized by bearish pressure and range-bound behavior, expected to last until August 2, 2027 [13] - The combination of the structural breakdown, weak Guna Triads, and bearish monthly trends suggests that BDX is not positioned for recovery in the near term [14][15]

Core Viewpoint - Changlian Co., Ltd. has established long-term strategic partnerships with several Fortune 500 companies, including Pop Mart and other industry leaders [1] Company Partnerships - The company has formed collaborations with notable firms such as Apple, BD, BOC Healthcare, Seiko, Mitsubishi, Hissen Meikang, Jaguar Land Rover, Baxter, and Kobayashi [1]

Becton, Dickinson and Company (NYSE:BDX) Goldman Sachs 46th Annual Global Healthcare Conference June 9, 2025 2:00 PM ET Company Participants Thomas E. Polen - President, CEO & Chairman Conference Call Participants Robert Justin Marcus - JPMorgan Chase & Co, Research Division Unidentified Analyst Yes. One additional disclosure that we needed. So the session is not open to the press. There you go. All right. So I want to thank Tom Polen, Chairman and Chief Executive Officer of Becton, Dickinson. I appreciate ...

Summary of Becton, Dickinson and Company (BDX) FY Conference Call Company Overview - **Company**: Becton, Dickinson and Company (BDX) - **Date of Conference**: June 09, 2025 Key Points Industry and Market Dynamics - **Separation Process**: The company is in the process of separating its biosciences or life sciences segment, with an announcement expected between Labor Day and Memorial Day [2][3][4] - **Market Complexity**: BDX operates in a complex medtech portfolio, being the only medtech company with exposure to both life sciences and pharma device markets [31] - **Revenue Growth**: BDX has experienced a 5.6% revenue CAGR since launching BD 2025 in 2021, with current guidance for this year at 3.25% [32] Financial Performance - **Headwinds**: The company faces headwinds from a slowdown in research spending, destocking in the pharma medical device channel, and challenges in the Chinese market, which collectively have impacted growth by approximately 180 basis points [33][34] - **China Exposure**: Currently, 5% to 6% of revenue comes from China, expected to decrease to about 4% post-separation [35] - **Profitability**: Despite challenges, BDX has managed to expand gross margins by 190 basis points last quarter, achieving 8% EPS growth [92] Strategic Focus - **Shareholder Value**: The company is focused on maximizing shareholder value through potential separation options, including spin-offs or sales [6][14] - **Use of Proceeds**: Any proceeds from a sale will likely be used for stock buybacks, as the company views this as a strong investment opportunity at current price levels [22][23] - **Innovation Pipeline**: BDX has a robust innovation pipeline, with significant product launches planned for 2026, including advancements in biologic drug delivery and new medical devices [72][94] Challenges and Outlook - **Macro Challenges**: The company is navigating macroeconomic challenges, particularly in China and life sciences spending, but remains optimistic about revenue growth and operational performance [91] - **Future Growth**: Long-term growth expectations remain positive, with a projected return to high single-digit growth in the biologics space as the destocking phase concludes [73] Additional Insights - **Tariff Impact**: BDX anticipates $90 million in tariff exposure for FY 2025, primarily affecting Q4, but expects a net positive impact for FY 2026 due to recent tariff reductions [81][82] - **Legislative Considerations**: The company is closely monitoring legislative changes that could impact funding for healthcare providers and the medtech industry [85][86] Conclusion Becton, Dickinson and Company is strategically positioned to navigate current market challenges while focusing on innovation and shareholder value. The upcoming separation of its life sciences segment and a strong pipeline of new products are expected to drive future growth.

Core Viewpoint - Becton, Dickinson and Company (NYSE: BDX) is identified as a leading provider of medical supplies with significant undervaluation and a high dividend yield of nearly 2.5%, the highest in over a decade [1] Company Overview - Becton, Dickinson operates in various sectors including life sciences, infusion, and diagnostics [1] - The company is noted for its excellent dividend safety, making it an attractive option for dividend growth investors [1] Investment Strategy - The focus is on identifying undervalued large-cap stocks with sustainable dividend growth and potential for capital appreciation [1] - There is also an interest in tech and small- or mid-cap stocks for their growth potential, regardless of dividend status [1] Performance Metrics - The dividend yield of BDX is highlighted as being the highest in over ten years, indicating strong performance in terms of returns to shareholders [1]

Core Viewpoint - Becton, Dickinson and Company (BDX) has issued an urgent update regarding its esophagogastric balloon tamponade tubes due to safety concerns following one reported death and two serious injuries related to the device's use [1][2][4]. Company Update - The FDA has highlighted BD's updated instructions for the device, emphasizing potential hazards and the importance of proper usage procedures [2][6]. - BD has a market capitalization of $49.59 billion and an earnings yield of 8.1%, which is higher than the industry average of 5.3% [5]. Stock Performance - Following the announcement, BDX shares traded flat until Thursday's closing, with a year-to-date decline of 23.4%, compared to the industry's 0.8% decline and the S&P 500's 0.3% loss [3]. Safety Concerns - The FDA's safety communication was prompted by issues with the device during the pre-use phase, particularly difficulties in removing plastic plugs, which could damage the device [6][8]. - Complications from these issues could delay diagnosis or treatment, potentially worsening patient outcomes [8]. Response Measures - In response to the incidents, BD has communicated revised preparation steps to customers, including specific methods for safely removing plugs from the device [9][10]. - BD is reinforcing training across healthcare facilities and reviewing product handling instructions to enhance patient safety [10].

Core Insights - BD (Becton, Dickinson and Company) is initiating a patient data registry for the Rotarex™ Atherectomy System to evaluate real-world outcomes for patients with peripheral artery disease (PAD) [1][2]. Group 1: Registry Details - The registry, named "XTRACT," is a prospective, multi-center, single-arm, post-market study aimed at assessing the clinical performance of the Rotarex™ Atherectomy System in treating U.S. patients with PAD lesions [3]. - The XTRACT Registry will enroll up to 600 patients across approximately 100 clinical sites in the United States, with the first patient expected to be enrolled later this year [3]. - Clinical follow-up evaluations will be conducted at 30 days, 6 months, and 12 months post-procedure to assess safety and effectiveness [3]. Group 2: Clinical Significance - The registry aims to provide valuable data to support clinical decision-making and enhance patient outcomes in managing PAD [4]. - The Rotarex™ Atherectomy System is designed to efficiently remove plaque and thrombus in peripheral arteries, serving dual purposes as both an atherectomy and thrombectomy device [4]. - The XTRACT Registry is the first comprehensive registry focused on real-world applications of the Rotarex™ System, highlighting BD's commitment to optimizing treatment strategies in collaboration with leading physicians [5]. Group 3: Industry Context - PAD affects over 21 million Americans and more than 200 million people globally, posing risks of cardiovascular complications and lower limb amputation [5]. - BD's initiative reflects its ongoing commitment to innovative technological development and evidence-based research to support physicians and improve patient outcomes [5].

Core Viewpoint - The article discusses the recent developments regarding the temporary final rule (IFR) issued by the U.S. government on January 16, 2025, which restricts the export of certain flow cytometers to China. The company, BD, is actively communicating with the U.S. government to seek revisions to this rule and has successfully obtained export licenses to continue serving its customers in China [1][3][5]. Summary by Sections - The U.S. government has approved BD's export license application, allowing the company to continue providing flow cytometers to its customers in China. This approval is seen as a positive step towards compliance with U.S. regulations [3][4][5]. - BD has received its first export license on April 18, 2025, which permits the sale, delivery, installation, and servicing of BD's spectral and 26+ channel flow cytometers in China. This license provides a clear path for BD to operate within the regulatory framework [1][3][4]. - The company is now officially restarting marketing efforts for several instruments in China, including the BD FACSDiscover™ S8 cell sorter and various models of the BD FACSymphony™ series, aiming to establish new collaborations [4][5].

Core Insights - The studies published in The Lancet Oncology and Cancer Medicine reveal that cancer patients are at a significantly higher risk of developing antimicrobial resistant (AMR) infections compared to non-cancer patients, highlighting the urgent need for improved infection control measures in this vulnerable population [1][2][4]. Study Findings - The studies are the first large, multi-center investigations quantifying AMR among cancer patients in the U.S., providing strong evidence that superbugs pose a substantial risk across various healthcare settings [2][6]. - AMR rates among key pathogens were found to be 1 to 3 times higher in outpatient cancer patients, with some specific pathogen-source combinations showing up to 5 times greater rates compared to non-cancer patients [6][8]. - Hospitalized cancer patients were found to be 1.5 to 2 times more likely to encounter AMR infections than their non-cancer counterparts [6][8]. Implications for Cancer Care - The emergence of AMR threatens the effectiveness of antibiotics, which are crucial for treating infections and preventing complications during cancer treatments such as chemotherapy and surgery [3][4]. - The findings suggest that the rapid rise of AMR could undermine new cancer therapies, including CAR T-cell therapy and other immunotherapies, due to the associated risks of immunosuppression and opportunistic infections [3][4]. Recommendations - The studies emphasize the need for enhanced infection prevention programs, focused antibiotic stewardship, and the increased use of rapid diagnostic tools to better manage AMR risks in cancer patients [4][6].